Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Open-Label, Three-Sequence, Three-Period, Partially Replicated Bioequivalence Study of Single-Dose ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions.

NCT07753902 is registered in ClinicalTrials.gov with Jiangsu Aidea Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07753902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07753902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Open-Label, Three-Sequence, Three-Period, Partially Replicated Bioequivalence Study of Single-Dose ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions.
Lead sponsor
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 10, 2026
Completion date
June 12, 2026
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus (hiv) infection